About Tigenix (NASDAQ:TIG)
Tigenix logoTiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases. The company?s lead product candidate is the Cx601, which completed Phase III clinical trials for the treatment of complex perianal fistulas in patients suffering from Crohn?s disease. It also engages in developing Cx611, a clinical stage product candidate from its expanded adipose-derived stem cell-based (eASC-based) technology platform, which completed a Phase I study in sepsis and a Phase I/IIa trial for the treatment of refractory rheumatoid arthritis; and Cx621, which has completed a Phase I trial for the treatment of intra lymphatic administration of allogeneic eASCs. It is also developing AlloCSC-01, a product candidate based on the CSC-based platform, which is in the second stage of a European Phase I/II trial in acute myocardial infarction; and AlloCSC-02 that is in a preclinical proof of concept stage for a chronic cardiac indication. The company has operations primarily in Belgium, Spain, and the United States. TiGenix NV was founded in 2000 and is headquartered in Leuven, Belgium.
Receive TIG News and Ratings via Email
Sign-up to receive the latest news and ratings for TIG and its competitors with MarketBeat's FREE daily newsletter.
Your Email Address
Sign-Up Now (Free)
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TIG
CUSIPN/A
Webwww.tigenix.com
Phone321-639-6060
Debt
Debt-to-Equity Ratio0.10%
Current Ratio1.37%
Quick Ratio1.36%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$29.65 million
Price / Sales10.93
Cash Flow$0.69 per share
Price / Cash36.35
Book Value$6.78 per share
Price / Book3.68
Profitability
Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees80
Outstanding Shares13,000,000
Tigenix (NASDAQ:TIG) Frequently Asked Questions
What is Tigenix's stock symbol?
Tigenix trades on the NASDAQ under the ticker symbol "TIG."
Where is Tigenix's stock going? Where will Tigenix's stock price be in 2017?
3 brokerages have issued 12-month price targets for Tigenix's shares. Their forecasts range from $19.00 to $30.00. On average, they expect Tigenix's stock price to reach $24.50 in the next twelve months. View Analyst Ratings for Tigenix.
What are Wall Street analysts saying about Tigenix stock?
Here are some recent quotes from research analysts about Tigenix stock:
1. According to Zacks Investment Research, "TiGenix NV is a biopharmaceutical company. It focused on developing and commercializing novel therapeutics for allogeneic or donor-derived, expanded stem cells. The company's product platform consists of Cx601 and Cx611 which are in clinical trial stage. It operates primarily in Madrid, Spain. TiGenix NV is based in Leuven, Belgium. " (10/21/2017)
2. Canaccord Genuity analysts commented, "We are particularly interested in the further safety data releases during the upcoming medical conferences, which will provide us with more information to better assess the long-term value and viability of the AlloCSCs platform." (3/13/2017)
Who are some of Tigenix's key competitors?
Some companies that are related to Tigenix include Collegium Pharmaceutical (COLL), GlycoMimetics (GLYC), Keryx Biopharmaceuticals (KERX), Deciphera Pharmaceuticals (DCPH), Uniqure (QURE), La Jolla Pharmaceutical (LJPC), Hanger (HNGR), Rigel Pharmaceuticals (RIGL), Tactile Systems Technology (TCMD), Clementia Pharmaceuticals (CMTA), Mesa Laboratories (MLAB), Urogen Pharma (URGN), Community Health Systems (CYH), Surgery Partners (SGRY), Mirati Therapeutics (MRTX), Mesoblast (MESO), Sinovac Biotech (SVA) and Atara Biotherapeutics (ATRA).
When did Tigenix IPO?
(TIG) raised $26 million in an initial public offering on Thursday, December 15th 2016. The company issued 2,800,000 shares at a price of $9.12 per share. BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Canaccord Genuity was co-manager.
Who owns Tigenix stock?
Tigenix's stock is owned by a variety of of retail and institutional investors. Top institutional investors include EAM Investors LLC (0.12%). Company insiders that own Tigenix stock include John Anderson and Palisade Global Investments Lt. View Institutional Ownership Trends for Tigenix.
Who sold Tigenix stock? Who is selling Tigenix stock?
Tigenix's stock was sold by a variety of institutional investors in the last quarter, including EAM Investors LLC. View Insider Buying and Selling for Tigenix.
How do I buy Tigenix stock?
Shares of Tigenix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tigenix's stock price today?
One share of Tigenix stock can currently be purchased for approximately $24.92.
How big of a company is Tigenix?
Tigenix has a market capitalization of $281.67 million and generates $29.65 million in revenue each year. Tigenix employs 80 workers across the globe.